Compare FTRE & LMRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | LMRI |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2025 |
| Metric | FTRE | LMRI |
|---|---|---|
| Price | $15.82 | $14.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $15.56 | ★ $22.67 |
| AVG Volume (30 Days) | ★ 1.4M | 638.5K |
| Earning Date | 03-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,759,900,000.00 | $1,003,375,000.00 |
| Revenue This Year | $3.17 | $9.29 |
| Revenue Next Year | $0.07 | $5.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | 1.38 |
| 52 Week Low | $3.97 | $14.00 |
| 52 Week High | $19.00 | $19.45 |
| Indicator | FTRE | LMRI |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | N/A |
| Support Level | $16.98 | N/A |
| Resistance Level | $17.24 | N/A |
| Average True Range (ATR) | 1.11 | 0.00 |
| MACD | -0.36 | 0.00 |
| Stochastic Oscillator | 13.64 | 0.00 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists' interpretations of those studies.